eubiologics

ȸ»ç¼Ò°³

Global biopharmaceutical company providing safety, health and future

ȸ»ç¿¬Çõ

(ÁÖ)À¯¹ÙÀÌ¿À·ÎÁ÷½º´Â Áö¼ÓÀûÀÎ ±â¾÷ °æÀï·Â °­È­¿Í °æ¿µÇõ½ÅÀ¸·Î ¼¼°è °øÁߺ¸°Ç ÁõÁø¿¡ ±â¿©ÇÏ´Â ±Û·Î¹ú ±â¾÷À¸·Î ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù.

2020

  • 10¹Ì±¹ POP BiotechÞä¿Í Joint Venture EUPOP Life sciences ¼³¸³

2019

  • 12ÀÌõ¸¸ºÒ ¼öÃâÀÇ Å¾ ¼ö»ó
  • 04Ãáõ Á¦2°øÀå(V Plant) ÁØ°ø

2018

  • 12ÀÏõ¸¸ºÒ ¼öÃâÀÇ Å¾ ¼ö»ó
  • 03Ãáõ Á¦2°øÀå(V Plant) °Ç¼³ Âø°ø

2017

  • 12EcML ±â¼úÀÌÀü °è¾à(KIST)
  • 08À¯ºñÄÝ-Ç÷¯½º WHO PQ ½ÂÀÎ
  • 01ÄÚ½º´Ú »óÀå

2016

  • 10À¯ºñÄÝ ¼öÃâ°³½Ã(¾ÆÀÌƼ 1¹é¸¸ µµ½º ¿Ü)
  • 06À¯ºñÄÝ¢ç UNICEF¿Í LTA(Long Term Agreement) ü°á

2015

  • 12À¯ºñÄÝ¢ç WHO PQ ÀÎÁõ
  • 01À¯ºñÄÝ¢ç Çѱ¹(MFDS) ¼öÃâÇã°¡

2014

  • 09OCV(À¯ºñÄÝ¢ç) ¿ø·áÀǾàÇ° ½Ã¼³Áõ¼³ (w.v.600L)
  • 08OCV(À¯ºñÄÝ¢ç) Çʸ®ÇÉ¿¡¼­ ÀÓ»ó3»ó ¼º°ø
  • 08GHIF(°ÔÀÌÃ÷Àç´Ü Áö¿øÆݵå) ÅõÀÚ À¯Ä¡

2013

  • 12OCV(À¯ºñÄÝ¢ç) Çʸ®ÇÉ¿¡¼­ ÀÓ»ó 3»ó IND ½ÂÀÎ

2012

  • 07OCV(À¯ºñÄÝ¢ç) Çѱ¹¿¡¼­ ÀÓ»ó1»ó IND½ÂÀÎ
  • 06Â÷¼¼´ë ÀåƼǪ½º ¹é½Å±â¼ú°³¹ß ¼öÇà (Áß¼Ò±â¾÷û)
  • 03ÁÖ½Äȸ»ç À¯¹ÙÀÌ¿ÀÆÊ ÇÕº´
  • 02º¥Ã³±â¾÷ ÀÎÁõ

2010

  • 12Tech. Transfer ¹× Feasibility study ½Ç½Ã
  • 09±¹Á¦¹é½Å¿¬±¸¼Ò(IVI)¿Í °æ±¸¿ë ÄÝ·¹¶ó¹é½Å(OCV, Oral Cholera Vaccine) ±â¼úÀÌÀü °è¾à
  • 03ÁÖ½Äȸ»ç À¯¹ÙÀÌ¿À·ÎÁ÷½º ¼³¸³